NCT00053989 · OUTCOME

PFS

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders · Source last updated 2020-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: 1 year

What was measured

Progression free survival defined as time from HSC infusion (day 0) until progression of disease or death due to any cause. Patients are censored if alive without disease progression through 1 year after HSC infusion

Groups in this outcome

All Patients

All patients enrolled on study

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Patients	41

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
All Patients	27	Not reported	13	40	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
13
upper Limit
40
value
27

denoms

counts
group Id
OG000
value
41
units
Participants

description

dispersion Type

95% Confidence Interval

groups

description
All patients enrolled on study
id
OG000
title
All Patients

param Type

NUMBER

reporting Status

POSTED

time Frame

1 year

title

PFS

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice